Signium Italy

AMT Genova S.p.A., Azienda che gestisce “in house” il Trasporto Pubblico Locale nella Città Metropolitana di Genova, con circa 3.000 dipendenti ed una flotta di circa 900 bus, la Metropolitana, la Ferrovia Genova - Casella, gli Impianti Verticali (Funicolari, Cremagliera e Ascensori) ed un servizio via mare, ha incaricato Signium Italia, divisione di GC Governance Consulting, di ricercare e selezionare il Direttore Generale. L’avviso è rivolto a candidature con un solido profilo manageriale, che abbiano maturato una significativa esperienza in analoghe posizioni apicali presso aziende di TPL, di grandi dimensioni, caratterizzate da rilevante complessità gestionale e organizzativa e multimodalità trasportistica.  Il termine ultimo per candidarsi alla selezione sono le ore 23.59 del 25 settembre 2024.  Per candidarsi fare esclusivo riferimento all’avviso pubblicato su: https://lnkd.in/gTyAgnWm che contiene le informazioni di dettaglio sulla posizione e l’informativa sulla privacy. La ricerca è da intendersi rivolta ad ambo i sessi (L.903/77 e L.125/91).  Saranno accettate solo candidature pervenute nel rispetto della procedura specificata nell’avviso e nel rispetto dei termini indicati.

Artificial Intelligence is becoming increasingly present in today’s professional world. It has very clear implications, e.g. when it comes to generating new models such as the one described in the attached article based on research made at ETH Zurich (Eidgenössische Technische Hochschule Zürich), one that can predict where a chemical entity can be modified and how to test its pharmaceutical impact. AI is less predictible when it comes to assess new organizational paradigms. The attached document (thank you New Line Ricerche di Mercato) shows how the drastic reduction of General Practicioners is already affecting the Physician/Patient relationship (e.g. diagnosis made on-line!). AI will play a substantial role in shaping this evolving relationship. It is also influencing how the Healthcare industry will adapt to those new paradigms. And you, how do you see AI impact your organizations in sales, marketing, HR, Finance? #Signium GC Governance Consulting #AI #Leadership

Up to 36 million people in the European Union live with a rare disease and 400 million worldwide. As many as 95% do not get adequate treatment. Rare disease do present a societal concern and a large share of the overall cost burden is borne by the families. More on this topic on @tinyurl.com/3khx9869 Signium Chiesi Group #lifesciences #pharmaeconomics #raredisease

We are happy to announce the arrival of Thibaud Eckenschwiller as Senior Advisor of the Signium Italian Team. He will be responsible for the development of the practice Pharma Life Science segment.   Thibaud is a Senior Executive who has gained thirty years of professional experience in CEO/General Management, Business Development, Marketing and Finance roles within diversifying companies in the Pharma sector, both in Italy and abroad.   Excellent knowledge of the Pharma/Lifescience segment, developed both within multinational companies, both in entrepreneurial companies and in start-up contexts. Signium Italy #SeniorAdvisor #Pharmaceutical #ExecutiveSearch

The month of October started with a lot of news that we are pleased to share with you.   Patrizia Ghiazza was in Nashville last week for the board meeting and annual Signium global conference! It was great to come together with colleagues from around the world to reconnect, deep dive into best practices, engage with industry experts, and strengthen our bond as a global community. By sharing insights, experience, and expertise, we aim to cultivate a stronger network, learn from one another, and collectively elevate our ability to deliver exceptional results for our clients & partners. #signium #signiumitaly #leadership #executivesearch